Mitochondrial CypD Acetylation Promotes Endothelial Dysfunction and Hypertension

Area of Science:

• Cardiovascular Science
• Mitochondrial Biology
• Hypertension Research

Background:

• Hypertension affects nearly half of adults, posing a significant cardiovascular disease risk.
• Mitochondrial hyperacetylation is implicated in hypertension, but specific protein roles remain unclear.
• This study investigates the role of cyclophilin D (CypD) acetylation at K166 in endothelial dysfunction and hypertension.

Purpose of the Study:

• To determine if CypD acetylation at K166 contributes to endothelial dysfunction and hypertension.
• To elucidate the regulatory mechanisms of CypD acetylation involving GCN5L1 and Sirt3.
• To evaluate potential therapeutic strategies targeting CypD acetylation.

Main Methods:

• Studied CypD acetylation in hypertensive patients and utilized CypD-K166R mutant and endothelial-specific GCN5L1-deficient mice.
• Employed an angiotensin II (Ang II) model of hypertension.
• Assessed mitochondrial protein acetylation, oxidative stress, endothelial function, and vascular metabolism.

Main Results:

• Hypertensive patients showed increased CypD acetylation, reduced Sirt3, and elevated GCN5L1.
• CypD-K166R mutant mice were protected against Ang II-induced hypertension and endothelial dysfunction.
• GCN5L1 depletion in endothelial cells prevented Ang II-induced oxidative stress and preserved endothelial function.

Conclusions:

• CypD acetylation at K166 plays a pathogenic role in endothelial dysfunction and hypertension.
• Targeting mitochondrial isolevuglandins and GCN5L1 may reduce CypD acetylation.
• These findings suggest potential therapeutic benefits for cardiovascular disease.